Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Head and Neck Squamous Cell Carcinoma
Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer
Posted inAI Oncology Pathology & Lab Medicine

Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer

Posted by MedXY By MedXY 10/24/2025
This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.
Read More
Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma
Posted inClinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

Posted by MedXY By MedXY 09/04/2025
A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.
Read More
  • uGMI: A More Accurate Alternative to HbA1c for Diabetes Management
  • Advancing Personalized Treatment in Papillary Thyroid Cancer: A Machine-Learning Model for Predicting Occult Lymph Node Metastasis
  • Long-term Air Pollution Linked to Adverse Body Composition Changes in Older Adults with Metabolic Syndrome
  • Bradykinin’s Modest Role in Sacubitril/Valsartan’s Blood Pressure Effects Revealed
  • Revolutionary Sixth-Generation Troponin Assay Doubles Early MI Rule-Out Capacity
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in